SA96160645B1 - عملية لتحضير جسيمات صالحه للتنفس - Google Patents
عملية لتحضير جسيمات صالحه للتنفس Download PDFInfo
- Publication number
- SA96160645B1 SA96160645B1 SA96160645A SA96160645A SA96160645B1 SA 96160645 B1 SA96160645 B1 SA 96160645B1 SA 96160645 A SA96160645 A SA 96160645A SA 96160645 A SA96160645 A SA 96160645A SA 96160645 B1 SA96160645 B1 SA 96160645B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- solvent
- compound
- inhalation
- inhalation compound
- particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000002904 solvent Substances 0.000 claims abstract description 38
- 239000000843 powder Substances 0.000 claims abstract description 32
- 238000013019 agitation Methods 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 14
- 239000012296 anti-solvent Substances 0.000 claims description 14
- 229960004436 budesonide Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 229960004017 salmeterol Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229960002714 fluticasone Drugs 0.000 claims description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 4
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 4
- 229950004432 rofleponide Drugs 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 229960000195 terbutaline Drugs 0.000 claims description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 229940124630 bronchodilator Drugs 0.000 claims description 3
- 239000000168 bronchodilator agent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003172 expectorant agent Substances 0.000 claims description 3
- 150000002617 leukotrienes Chemical class 0.000 claims description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 229940066493 expectorants Drugs 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- HXQQNYSFSLBXQJ-UHFFFAOYSA-N COC1=C(NC(CO)C(O)=O)CC(O)(CO)CC1=NCC(O)=O Chemical compound COC1=C(NC(CO)C(O)=O)CC(O)(CO)CC1=NCC(O)=O HXQQNYSFSLBXQJ-UHFFFAOYSA-N 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 241000152982 Laelia <moth> Species 0.000 claims 1
- 102100026918 Phospholipase A2 Human genes 0.000 claims 1
- 101710096328 Phospholipase A2 Proteins 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 235000015107 ale Nutrition 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 10
- 239000011521 glass Substances 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000005297 pyrex Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- -1 fumarate dihydrate Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229950000339 xinafoate Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- NUBLQEKABJXICM-FQEVSTJZSA-N (1r)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1[C@@H](O)CNCCCCCCOCCC1=CC=CC=N1 NUBLQEKABJXICM-FQEVSTJZSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- RFAZFSACZIVZDV-UHFFFAOYSA-N butan-2-one Chemical compound CCC(C)=O.CCC(C)=O RFAZFSACZIVZDV-UHFFFAOYSA-N 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229950004618 picumeterol Drugs 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501384A SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Process for the preparation of respirable particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA96160645B1 true SA96160645B1 (ar) | 2005-07-05 |
Family
ID=20397958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA96160645A SA96160645B1 (ar) | 1995-04-13 | 1996-03-04 | عملية لتحضير جسيمات صالحه للتنفس |
Country Status (22)
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| SE9701956D0 (sv) | 1997-05-23 | 1997-05-23 | Astra Ab | New composition of matter |
| CA2295076A1 (en) * | 1997-06-27 | 1999-01-07 | Astra Aktiebolag | New combination of antiasthma medicaments |
| SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| GB9806477D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved crystals |
| GB2341120B (en) | 1998-09-04 | 2002-04-17 | Aea Technology Plc | Controlling uniformity of crystalline precipitates |
| SE9803770D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Dry powder pharmaceutical formulation |
| SE9804001D0 (sv) * | 1998-11-23 | 1998-11-23 | Astra Ab | New process |
| GB9826284D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9826286D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9828721D0 (en) * | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
| GB9905512D0 (en) * | 1999-03-10 | 1999-05-05 | Smithkline Beecham Plc | Process |
| GB9919693D0 (en) * | 1999-08-19 | 1999-10-20 | Rhone Poulenc Rorer Ltd | Process |
| CZ20011726A3 (cs) | 2000-05-26 | 2002-02-13 | Pfizer Products Inc. | Způsob reakční krystalizace, který umoľňuje řídit velikost částic |
| GB0015981D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| GB0016040D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| GB0016002D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| US7037528B2 (en) | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6960256B2 (en) | 2001-05-05 | 2005-11-01 | Accentus Plc | Formation of small crystals |
| DE10137017A1 (de) * | 2001-07-30 | 2003-02-20 | Basf Ag | Kristallisationsverfahren zur Einstellung kleiner Partikel |
| ATE336231T1 (de) * | 2001-08-29 | 2006-09-15 | Dow Global Technologies Inc | Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung |
| US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| EP1429749A2 (en) * | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
| JP2003221335A (ja) | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
| US8541399B2 (en) | 2002-02-19 | 2013-09-24 | Resolution Chemicals Limited | Solvent-based sterilisation of pharmaceuticals |
| DE10214031A1 (de) * | 2002-03-27 | 2004-02-19 | Pharmatech Gmbh | Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation |
| FI20020857A7 (fi) * | 2002-05-07 | 2003-11-08 | Focus Inhalation Oy | Amorfisen aineen muuntaminen vastaavaksi kiteiseksi aineeksi spraykuivaamalla ja käyttämällä kiteistä spraykuivattua ainetta lääkevalmisteissa |
| WO2004002551A2 (en) * | 2002-06-28 | 2004-01-08 | Advanced Inhalation Research, Inc. | Inhalable epinephrine |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
| US20040028746A1 (en) * | 2002-08-06 | 2004-02-12 | Sonke Svenson | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| US20040028747A1 (en) * | 2002-08-06 | 2004-02-12 | Tucker Christopher J. | Crystalline drug particles prepared using a controlled precipitation process |
| KR20050056222A (ko) * | 2002-09-30 | 2005-06-14 | 아쿠스피어 인코포레이티드 | 흡입용 지속 방출형 다공성 미세입자 |
| US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| WO2004066912A2 (en) * | 2003-01-31 | 2004-08-12 | Technion Research & Development Foundation Ltd. | Anti-inflammatory compositions and uses thereof |
| GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| SI1610878T1 (sl) * | 2003-02-21 | 2015-02-27 | University Of Bath | Postopek za proizvodnjo delcev |
| US7041144B2 (en) * | 2003-03-04 | 2006-05-09 | Five Star Technologies, Inc. | Hydrodynamic cavitation crystallization process |
| US7511079B2 (en) * | 2003-03-24 | 2009-03-31 | Baxter International Inc. | Methods and apparatuses for the comminution and stabilization of small particles |
| US20060182808A1 (en) * | 2003-04-29 | 2006-08-17 | Akzo Nobel N.V. | Antisolvent solidification process |
| WO2004110585A1 (ja) * | 2003-06-10 | 2004-12-23 | Taisho Pharmaceutical Co., Ltd. | 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 |
| SE0302029D0 (sv) * | 2003-07-07 | 2003-07-07 | Astrazeneca Ab | Novel process |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| US20050196416A1 (en) * | 2004-02-05 | 2005-09-08 | Kipp James E. | Dispersions prepared by use of self-stabilizing agents |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2005105065A2 (en) * | 2004-05-05 | 2005-11-10 | Renopharm Ltd. | Thiazole-based nitric oxide donors for treating inflammatory bowel diseases |
| US7498445B2 (en) * | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
| US7968575B2 (en) * | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| WO2005105278A2 (en) * | 2004-05-05 | 2005-11-10 | Akzo Nobel N.V. | Antisolvent emulsion solidification process |
| US8134010B2 (en) * | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
| US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| WO2006045795A2 (en) * | 2004-10-29 | 2006-05-04 | Akzo Nobel N.V. | Processes involving the use of antisolvent crystallization |
| US20060120972A1 (en) * | 2004-11-09 | 2006-06-08 | Peter Engels | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension |
| DE102005011786A1 (de) | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| US20090186088A1 (en) * | 2005-03-18 | 2009-07-23 | Nanomaterials Technology Pte Ltd | Inhalable drug |
| EP1868577A4 (en) | 2005-04-15 | 2009-12-09 | Reddys Lab Inc Dr | Lacidipine PARTICLE |
| US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
| AU2006269961B2 (en) * | 2005-07-15 | 2012-07-19 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| WO2007009164A1 (en) * | 2005-07-15 | 2007-01-25 | Eiffel Technologies Limited | Method of particle formation |
| US20070026073A1 (en) * | 2005-07-28 | 2007-02-01 | Doney John A | Amorphous efavirenz and the production thereof |
| US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
| EP1954245A2 (en) * | 2005-11-15 | 2008-08-13 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
| EP1973523A2 (en) * | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| US20070148211A1 (en) * | 2005-12-15 | 2007-06-28 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for oral administration |
| US7913223B2 (en) * | 2005-12-16 | 2011-03-22 | Dialogic Corporation | Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system |
| US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
| WO2008057048A1 (en) * | 2006-11-09 | 2008-05-15 | Nanomaterials Technology Pte Ltd | Nano & micro-sized particles of statin compounds and process for forming same |
| WO2008076780A2 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
| WO2008080037A2 (en) * | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Carotenoids of enhanced bioavailability |
| WO2008080047A2 (en) * | 2006-12-23 | 2008-07-03 | Baxter International Inc. | Magnetic separation of fine particles from compositions |
| US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
| JP5508859B2 (ja) * | 2007-01-26 | 2014-06-04 | アイエスピー インヴェストメンツ インコーポレイテッド | 噴霧乾燥製品を製造するための調剤処理方法 |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| EP2191821A1 (en) * | 2008-11-26 | 2010-06-02 | CHIESI FARMACEUTICI S.p.A. | Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation |
| CN102405044A (zh) | 2009-02-06 | 2012-04-04 | 南加利福尼亚大学 | 含有单萜的治疗组合物 |
| US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
| US20100294986A1 (en) * | 2009-05-19 | 2010-11-25 | Massachusetts Institute Of Technology | Supercritical fluid facilitated particle formation in microfluidic systems |
| US20100298602A1 (en) * | 2009-05-19 | 2010-11-25 | Massachusetts Institute Of Technology | Systems and methods for microfluidic crystallization |
| HUE026414T2 (hu) | 2009-07-15 | 2016-05-30 | Theravance Biopharma R&D Ip Llc | Bifenil-vegyület kristályos szabad-bázis formája |
| EP2477642A4 (en) * | 2009-09-17 | 2013-03-13 | Mutual Pharmaceutical Co | METHOD FOR THE TREATMENT OF ASTHMA WITH ANTIVIRUS AGENTS |
| HRP20181266T1 (hr) * | 2009-10-01 | 2018-10-05 | Adare Pharmaceuticals, Inc. | Kortikosteroidni pripravci za oralnu primjenu |
| US9889098B2 (en) | 2009-10-22 | 2018-02-13 | Vizuri Health Sciences Llc | Methods of making and using compositions comprising flavonoids |
| EP2542082B8 (en) | 2010-03-03 | 2020-06-17 | Neonc Technologies Inc. | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol |
| CN101849910B (zh) * | 2010-05-18 | 2012-02-22 | 重庆华邦制药股份有限公司 | 一种二丙酸倍他米松微粒的制备方法 |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| EP2883543B1 (en) | 2010-08-27 | 2016-11-16 | Neonc Technologies Inc. | Pharmaceutical compositions comprising perillyl alcohol carbamates |
| CA2812263A1 (en) | 2010-09-22 | 2012-03-29 | Map Pharmaceuticals, Inc. | Corticosteroid particles and method of production |
| EP3130579B1 (en) | 2010-12-17 | 2024-02-07 | University of Southern California | Conjugates of isoperillyl alcohol |
| CN102134236B (zh) * | 2011-04-15 | 2013-07-24 | 北方民族大学 | 微细克拉霉素粉体的制备方法 |
| CN103649104A (zh) * | 2011-07-08 | 2014-03-19 | 辉瑞股份有限公司 | 用于制备氟替卡松丙酸酯形式1的方法 |
| BR112014008114B1 (pt) | 2011-10-11 | 2022-07-26 | Chiesi Farmaceutici S.P.A. | Micropartículas cristalinas, formulação farmacêutica, inalador dosimetrado pressurizado, formulação farmacêutica, processo para preparar microparticulas cristalinas e uso de micropartículas cristalinas |
| DE102012221219B4 (de) * | 2012-11-20 | 2014-05-28 | Jesalis Pharma Gmbh | Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel |
| PL2968312T3 (pl) | 2013-03-15 | 2018-08-31 | Verona Pharma Plc | Kombinacja leków |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| EP3231444B1 (en) | 2014-05-12 | 2019-12-18 | Verona Pharma PLC | New treatment |
| JP6530480B2 (ja) * | 2014-07-08 | 2019-06-12 | アムファスター ファーマシューティカルズ，インコーポレイティド | 微小インスリン、微小インスリン類似体及びそれらの製造方法 |
| EP3261441B1 (en) | 2015-02-12 | 2020-09-09 | Neonc Technologies Inc. | Pharmaceutical compositions comprising perillyl alcohol derivatives |
| US10322168B2 (en) | 2016-01-07 | 2019-06-18 | Amphastar Pharmaceuticals, Inc. | High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| DK3547836T3 (da) | 2016-11-30 | 2024-11-18 | Univ Southern California | Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer |
| EP3749291B1 (en) | 2018-02-08 | 2024-01-03 | University of Southern California | Methods of permeabilizing the blood brain barrier |
| WO2020205539A1 (en) | 2019-03-29 | 2020-10-08 | Vizuri Health Sciences Consumer Healthcare, Inc. | Compositions and methods for the prevention and treatment of radiation dermatitis, eczema, burns, wounds and certain cancers |
| CN114262316A (zh) * | 2021-12-24 | 2022-04-01 | 嘉应学院 | 纳米橙皮素、其制备方法及所用双匀浆空化射流系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| CA1282405C (en) | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
| KR0132576B1 (ko) * | 1988-10-05 | 1998-04-17 | 로렌스 티. 웰츠 | 항-용매 내로의 침전을 통한 미분 고형물 결정 분말의 제조 방법 |
| GB9001635D0 (en) * | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
| CA2044706C (en) * | 1990-06-15 | 2003-02-25 | Michael Midler Jr. | Crystallization method to improve crystal structure and size |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5639441A (en) * | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
-
1995
- 1995-04-13 SE SE9501384A patent/SE9501384D0/xx unknown
-
1996
- 1996-03-04 SA SA96160645A patent/SA96160645B1/ar unknown
- 1996-04-01 TW TW085103802A patent/TW492877B/zh not_active IP Right Cessation
- 1996-04-01 ZA ZA962596A patent/ZA962596B/xx unknown
- 1996-04-02 IN IN723DE1996 patent/IN185119B/en unknown
- 1996-04-08 IL IL11784196A patent/IL117841A/en active IP Right Grant
- 1996-04-12 DK DK96910285T patent/DK0820276T3/da active
- 1996-04-12 US US08/669,477 patent/US6221398B1/en not_active Expired - Fee Related
- 1996-04-12 AT AT96910285T patent/ATE230257T1/de not_active IP Right Cessation
- 1996-04-12 JP JP8530963A patent/JPH11503448A/ja not_active Ceased
- 1996-04-12 EP EP96910285A patent/EP0820276B1/en not_active Revoked
- 1996-04-12 ES ES96910285T patent/ES2188750T3/es not_active Expired - Lifetime
- 1996-04-12 AU AU53524/96A patent/AU694863B2/en not_active Ceased
- 1996-04-12 CN CN96194372A patent/CN1102383C/zh not_active Expired - Fee Related
- 1996-04-12 NZ NZ305515A patent/NZ305515A/xx unknown
- 1996-04-12 PT PT96910285T patent/PT820276E/pt unknown
- 1996-04-12 AR AR33616796A patent/AR001624A1/es unknown
- 1996-04-12 WO PCT/SE1996/000479 patent/WO1996032095A1/en not_active Application Discontinuation
- 1996-04-12 CA CA002217062A patent/CA2217062A1/en not_active Abandoned
- 1996-04-12 DE DE69625589T patent/DE69625589T2/de not_active Revoked
- 1996-04-13 MY MYPI96001419A patent/MY117344A/en unknown
-
1997
- 1997-10-02 NO NO19974557A patent/NO316209B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2217062A1 (en) | 1996-10-17 |
| IN185119B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2000-11-18 |
| WO1996032095A1 (en) | 1996-10-17 |
| NO974557D0 (no) | 1997-10-02 |
| MY117344A (en) | 2004-06-30 |
| DK0820276T3 (da) | 2003-03-17 |
| IL117841A0 (en) | 1996-08-04 |
| SE9501384D0 (sv) | 1995-04-13 |
| PT820276E (pt) | 2003-04-30 |
| EP0820276B1 (en) | 2003-01-02 |
| AR001624A1 (es) | 1997-11-26 |
| DE69625589T2 (de) | 2003-09-25 |
| AU5352496A (en) | 1996-10-30 |
| NO974557L (no) | 1997-10-02 |
| JPH11503448A (ja) | 1999-03-26 |
| ES2188750T3 (es) | 2003-07-01 |
| EP0820276A1 (en) | 1998-01-28 |
| IL117841A (en) | 2004-01-04 |
| US6221398B1 (en) | 2001-04-24 |
| ZA962596B (en) | 1996-10-14 |
| NO316209B1 (no) | 2003-12-29 |
| CN1186428A (zh) | 1998-07-01 |
| CN1102383C (zh) | 2003-03-05 |
| DE69625589D1 (de) | 2003-02-06 |
| AU694863B2 (en) | 1998-07-30 |
| TW492877B (en) | 2002-07-01 |
| NZ305515A (en) | 1999-03-29 |
| ATE230257T1 (de) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA96160645B1 (ar) | عملية لتحضير جسيمات صالحه للتنفس | |
| EP2321023B1 (en) | Process for improving crystallinity of fluticasone particles | |
| MX2013008796A (es) | Formulaciones de particulas en polvo seco que contienen dos o mas ingredientes activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vias respiratorias. | |
| KR20010012821A (ko) | 부데소니드의 미분 결정질 입자를 함유하는 조성물 | |
| BRPI0316908B1 (pt) | preparo de suspensões aquosas estéreis incluindo ingredientes ativos cristalinos micronizados para inalação | |
| ES2251418T5 (es) | Partículas de inhalación: método de preparación | |
| US20090186088A1 (en) | Inhalable drug | |
| WO2004110585A9 (ja) | 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤 | |
| Gilani et al. | Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols | |
| AU2006225066B2 (en) | Inhalable drug | |
| CA2476621A1 (en) | Inhalation powder containing the cgrp antagonist bibn4096 and process for the preparation thereof | |
| WO2011018532A2 (en) | Steroid solvates | |
| WO2025120213A1 (en) | Tranexamic acid compositions | |
| Cook | Sustained release microparticles for pulmonary drug delivery |